Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1955 4
1966 1
1982 1
2000 1
2001 1
2004 3
2005 11
2006 13
2007 20
2008 14
2009 24
2010 30
2011 34
2012 38
2013 44
2014 47
2015 71
2016 60
2017 78
2018 80
2019 67
2020 77
2021 87
2022 68
2023 66
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

840 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Bataller A, et al. Among authors: jabbour e. Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285057. Online ahead of print. Haematologica. 2024. PMID: 38695144 Free article.
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.
Bhattarai KR, Mobley RJ, Barnett KR, Ferguson DC, Hansen BS, Diedrich JD, Bergeron BP, Yoshimura S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Cheng C, Pruett-Miller SM, Relling MV, Yang JJ, Evans WE, Savic D. Bhattarai KR, et al. Among authors: jabbour e. Nat Commun. 2024 May 1;15(1):3681. doi: 10.1038/s41467-024-48124-4. Nat Commun. 2024. PMID: 38693155 Free article.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y, Laird AD, Roberts KG, Yafawi RL, Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour EJ, Cassaday RD, Loyd MR, Olsen SR, Neale GA, Liu X, Vandendries E, Advani AS, Mullighan CG. Zhao Y, et al. Among authors: jabbour ej. Blood Adv. 2024 Mar 26:bloodadvances.2023012430. doi: 10.1182/bloodadvances.2023012430. Online ahead of print. Blood Adv. 2024. PMID: 38607410
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Short NJ, et al. Among authors: jabbour e. Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329. Online ahead of print. Am J Hematol. 2024. PMID: 38607091 No abstract available.
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Huang X, et al. Among authors: jabbour e. Cancer Cell. 2024 Apr 8;42(4):552-567.e6. doi: 10.1016/j.ccell.2024.03.003. Cancer Cell. 2024. PMID: 38593781 Free PMC article.
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Bose P, et al. Among authors: jabbour ej. Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2023.284078. Online ahead of print. Haematologica. 2024. PMID: 38572554 Free article. No abstract available.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS PhD, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: jabbour ej. Blood. 2024 Mar 29:blood.2024023930. doi: 10.1182/blood.2024023930. Online ahead of print. Blood. 2024. PMID: 38551807
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Bazinet A, et al. Among authors: jabbour e. Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6. Lancet Haematol. 2024. PMID: 38548404 Clinical Trial.
840 results